ACTRIMS Forum meeting – San Diego, California – February 5-7, 2026
Please note that the NeuroSens ACTRIMS Forum 2026 Highlights slide resource, developed in collaboration with Dr. Mark S. Freedman, Director of the MS Research Unit, The Ottawa Hospital, Ottawa, will be made available on request only. Healthcare professionals can request this slide presentation for self-study (view only) by completing the online form. For more information, contact us at info@neuro-sens.com. Read More
ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease
PrUltomiris® (ravulizumab) now publicly reimbursed for adult anti-AQP4 antibody-positive NMOSD in Ontario, Quebec, Alberta, Nova Scotia, Saskatchewan, and NIHB
Alexion, AstraZeneca Rare Disease is pleased to announce that as of January 20th, 2026, ravulizumab (Ultomiris) is now listed on the Ontario Drug Benefit program for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disease (NMOSD). Read More
The following summarizes some of the highlights from the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum, held February 5-7, 2026 in San Diego, California.